Stockreport

La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria

La Jolla Pharmaceutical Company  (LJPC) 
Last la jolla pharmaceutical company earnings: 3/2 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: lajollapharmaceutical.com/investor-relations
PDF -Orphan Drug Designation Program offers potentially up to seven years of marketing exclusivity- -NDA Submission Planned for Fourth Quarter of 2019- SAN DIEGO, Jul [Read more]